MLTX
MoonLake Immunotherapeutics
NASDAQ · Healthcare · Biotechnology · CH
$14.98
−1.38%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 1.6M | 2.6M | — | — | — |
| Gross Profit | (1.6M) | (2.6M) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 222.0M | 202.9M | 112.8M | 31.8M | 42.0M |
| SG&A Expense | 47.0M | 42.0M | 30.3M | 22.3M | 23.0M |
| General & Admin Expense | 47.0M | 42.0M | 30.3M | 22.3M | 23.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (2.2M) | (2.6M) | — | — | — |
| Total Operating Expenses | 266.7M | 242.2M | 143.1M | 54.1M | 65.1M |
| Cost and Expenses | 268.3M | 244.8M | 143.1M | 54.1M | 65.1M |
| Operating Income (EBIT) | (268.3M) | (244.8M) | (143.1M) | (54.1M) | (65.1M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 10.1M | 7.2M | — | — | — |
| Net Interest Income | (10.1M) | (7.2M) | — | — | — |
| Other Non-Op Income/Expense | 4.2M | 15.1M | 22.1M | 10.1M | 591.7K |
| Non-Operating Income (excl Interest) | (14.3M) | (22.4M) | (22.1M) | (10.1M) | (591.7K) |
| EBT (Pre-Tax Income) | (264.1M) | (229.7M) | (121.0M) | (44.0M) | (64.5M) |
| Income Tax Expense | 1.1M | 611.0K | 282.2K | 94.4K | 36.4K |
| Bottom Line | |||||
| Net Income | (263.7M) | (227.3M) | (118.9M) | (36.0M) | (50.0M) |
| Earnings from Cont. Ops | (265.2M) | (230.3M) | (121.2M) | (44.1M) | (64.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (263.7M) | (227.3M) | (118.9M) | (36.0M) | (50.0M) |
| Per Share | |||||
| Basic EPS | ($3.85) | ($3.53) | ($1.89) | ($0.73) | ($1.70) |
| Diluted EPS | ($3.85) | ($3.53) | ($1.89) | ($0.73) | ($1.70) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 73.9M | 64.5M | 62.9M | 49.1M | 29.4M |
| Diluted Shares Outstanding | 73.9M | 64.5M | 62.9M | 49.1M | 29.4M |
| Profitability Metrics | |||||
| EBITDA | (250.8M) | (219.8M) | (119.6M) | (43.6M) | (64.3M) |
| D&A | 3.2M | 2.6M | 1.4M | 370.3K | 164.8K |
| EBIT | (254.1M) | (222.5M) | (121.0M) | (44.0M) | (64.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026